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Teratocarcinoma-Derived Growth Factor-1 Is Upregulated
in Aldosterone-Producing Adenomas and Increases
Aldosterone Secretion and Inhibits Apoptosis In Vitro
Tracy A. Williams, Silvia Monticone, Fulvio Morello, Choong-Chin Liew, Giulio Mengozzi,
Catia Pilon, Sofia Asioli, Anna Sapino, Franco Veglio, Paolo Mulatero
Abstract—Aldosterone-producing adenomas (APA) are a frequent cause of secondary hypertension characterized by
autonomous hypersecretion of aldosterone. However, the molecular mechanisms involved in adrenal tumorigenesis and
deregulated aldosterone secretion are currently unknown. To identify putative functional genes, a transcriptional
screening was performed on 8 APA and 3 normal adrenals (NA) using oligonucleotide microarrays. Data were next
validated on an expanded set of samples by real-time PCR (APA, n19; NA, n10). The epidermal growth factor–like
teratocarcinoma-derived growth factor-1 (TDGF-1) was upregulated in APA compared with NA (14.7-fold and
21.4-fold by microarray and real-time PCR, respectively). In vitro studies and Western blot analysis using the NCI
H295R adrenocortical cell line showed that TDGF-1 increased Akt phosphorylation on Thr308 and Ser473, consistent
with activation of phosphatidylinositol 3-kinase/Akt signaling, and also demonstrated a concomitant inactivation of the Akt
substrate glycogen synthesis kinase-3 via Ser9 phosphorylation. Furthermore, TDGF-1 mediated a 3.80.4-fold
increase in aldosterone secretion (n4) that was specifically blocked by the phosphatidylinositol 3-kinase inhibitors
wortmannin (50 nmol/L) and LY294002 (20 mol/L). Finally, TDGF-1 protected H295R cells from apoptosis induced
by staurosporine, causing a decrease in caspase-3 activity, a reduction in the inactivation of poly(ADP-ribose)
polymerase, and an inhibition of DNA fragmentation, detected by the TUNEL reaction and fluorescence microscopy
that was blocked by LY294002. Taken together, our data suggest that TDGF-1, which is significantly upregulated in
APA and mediates aldosterone hypersecretion and deregulated growth in adrenocortical cells in vitro, may represent a
key player in the development and pathophysiology of primary aldosteronism. (Hypertension. 2010;55:00-00.)
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Primary aldosteronism (PA) is the most frequent form ofendocrine hypertension, accounting for up to 5% to 10%
of all hypertensive patients,1 and is characterized by the
chronic, excessive, and autonomous secretion of aldosterone
by the adrenal gland. The diagnosis of this form of
hypertension is fundamental because, compared with es-
sential hypertensives with similar risk profiles, patients
with PA are more prone to stroke and myocardial infarc-
tion2 and display an increase in cardiovascular damage and
metabolic complications.3
Aldosterone-producing adenomas (APA) are a common
underlying cause of PA and are found in 30% to 40% of PA
patients, whereas bilateral adrenal hyperplasia is present in
60% to 70% of patients.4 Unilateral adrenalectomy normal-
izes, or at least markedly improves, the blood pressure in
patients with APA, and therefore, APA is the most common,
specifically treatable, and potentially curable form of hyper-
tension.4,5 However, the molecular mechanisms underlying
the alterations in cell growth in the adrenal cortex and the
hypersecretion of aldosterone have not yet been defined.
Previous genomic analyses6–9 have provided evidence for
differential gene expression in APA compared with normal
adrenals (NA). The present study was undertaken to better
define upregulated gene transcripts in highly selected APA
and to investigate the functional role of such genes specifi-
cally with regard to autonomous aldosterone secretion and
deregulated cell growth. The APA used in this study were
removed from patients studied in our hypertension unit who
had been homogeneously selected following a rigorous diag-
nostic flowchart that includes adrenal venous sampling and
postadrenalectomy evaluation. Furthermore, strict criteria
were used for adrenal venous sampling, cannulation, and
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lateralization,10 and finally, NA and APA were removed
under identical conditions; that is, in both cases, the same
technique, surgical team, and anesthetic was used.
We demonstrate here, by microarray analysis and real-time
PCR, that teratocarcinoma-derived growth factor-1 (TDGF-1,
Cripto-1, CR-1), which belongs to the epidermal growth
factor–Cripto-FRL1-Cryptic (CFC) protein family and plays
a key role in early vertebrate development and carcinogene-
sis,11–13 is a highly upregulated gene in APA.11 Furthermore,
immunohistochemical studies show that this growth factor
displays a distinct localization to APA nuclei, in contrast to
the cytoplasmic expression observed in the surrounding
adrenal cortex and in the zona glomerulosa of NA tissue.
Functional studies of TDGF-1 in NCI H295R cells14
demonstrate that TDGF-1 mediates an activation of the
phosphatidylinositol 3-kinase (PI3K)/Akt signaling path-
way and both an increase in aldosterone secretion and an
inhibition of apoptosis in vitro. Furthermore, these latter 2
effects are specifically blocked by PI3K inhibitors. There-
fore, this study identifies a gene transcript upregulated in
APA that displays functional roles in vitro that are relevant
to the aldosterone hypersecretion and deregulated cell
growth typical of an APA.
Methods
An expanded Methods section is available online at http://hyper.
ahajournals.org.
Patient Selection
Patients were studied following the procedure described in detail
elsewhere.10 Clinical and biochemical data of the selected patients
before and after adrenalectomy are shown in Table 1.
Microarray
RNA samples used for microarray experiments (n12) were assayed
for purity and quality using an Agilent Bioanalyzer. The gene
expression profiling platform was oligonucleotide array Affymetrix
GeneChip HG-U133 Plus 2.0. cRNA synthesis, labeling, hybridization,
and chip scanning were performed following the manufacturer’s proto-
cols. CEL files were analyzed using dChip 2008 software.15
RNA Extraction From Adrenal Tissues
Adrenal tissue (100 mg) was homogenized (Ultra-Turrax T8 IKA
tissue homogenizer, Staufen, Germany) in 1 mL of TRI-reagent
(Sigma-Aldrich Corp, St. Louis, Mo) and processed according to the
manufacturer’s instructions.
Gene Expression Assays
Reverse transcription was performed using 5 g of total RNA, 250
ng of random primers, and SuperScript II reverse transcriptase
(Invitrogen Corp, Carlsbad, Calif), as described by the manufacturer.
Real-time PCR was performed in triplicate using TaqMan gene
expression assays (Applied Biosystems, Foster City, Calif) on an
Applied Biosystems ABI 7500 instrument following standard proto-
cols. Gene expression levels were analyzed using the 2Ct relative
quantification method, using -actin as the endogenous reference
gene.
Semiquantitative RT-PCR
Total RNA was extracted from 100-mm-diameter plates of subcon-
fluent cells (RNeasy mini kit, Qiagen, Valencia, Calif). First-strand
cDNA were generated from 5 g of total RNA using Superscript II
reverse transcriptase (Invitrogen) and used as templates for PCR
amplification of TDGF-1 or GAPDH cDNA fragments.
PCR Cloning of TDGF-1
The full-length coding region of the TDGF-1 cDNA was PCR
amplified from first-strand cDNA using pfu polymerase (Promega,
Madison, Wis) from an APA expressing the highest level of the
TDGF-1 transcript and inserted into pcDNA3.1. A control plasmid
was constructed (pcDNA3.1/control) comprising TDGF-1 cDNA in-
serted in the antisense direction with respect to the cytomegalovirus
promoter.
Immunohistochemistry
Frozen sections of APA or adjacent normal cortical adrenals (4 m)
were incubated for 1 hour with antihuman TDGF-1 polyclonal
antibody (ab19917, Abcam, Cambridge, United Kingdom; 200 L,
1:20 dilution). Bound primary antibody was visualized using the
Envision system horseradish peroxidase–labeled polymer (Dako,
Carpinteria, Calif) conjugated with anti-rabbit secondary antibody
and staining completed with 3,3-diaminobenzidine substrate-
chromogen. Nuclei were counterstained with hemalum.
Cell Culture
NCI H295R human adrenocortical carcinoma cells14 were cultured in
RPMI 1640 medium without phenol red (Gibco, Billings, Mont)
supplemented with 2% FBS, insulin-transferrin-selenium A,
L-glutamine (292 g/mL), streptomycin (100 g/mL), and penicillin
(100 U/mL) (all from Gibco) and maintained at 37°C in a humidified
5% CO2 incubator.
Transfection of H295R Cells
H295R cells (2106) were electroporated using 2 g of plasmid in
Nucleofector solution R (100 L) with the Amaxa nucleofector
(program P20, Amaxa Biosystems, Cologne, Germany).
Aldosterone Measurements
Culture medium was assayed for aldosterone in duplicate by radio-
immunoassay as described previously.10 Aldosterone measurements
were normalized using protein concentrations of cell lysates.16
Cell Proliferation Assay
Cell proliferation of transfected H295R cells was determined using
the Cell Titer 96 AQueous One solution cell proliferation assay kit
(Promega).
Apoptosis Assays
Poly(ADP-Ribose) Polymerase Assay
Transfected H295R cells were incubated with or without staurospo-
rine (STS; 500 nmol/L for 16 hours) and then washed, lysed, and
sonicated in SDS-PAGE sample buffer (300 L). Samples (15 L)
Table 1. Clinical and Biochemical Data of Patients Before and
After Adrenalectomy
Parameter Before Adrenalectomy After Adrenalectomy
Age, years 49 (30 to 66)
Sex, M/F 9/13
SBP, mm Hg 17818 1307
DBP, mm Hg 10810 825
PRA, ng ml1 hour1 0.26 (0.1 to 0.6) 2 (1 to 3.1)
PAC, ng/dL 54.7 (24.5 to 121.8) 9.3 (2.4 to 13.9)
ARR 321.5 (49 to 1218) 5 (2.5 to 11.7)
K, mEq/L 3.4 (2.4 to 4.2) 4.7 (4.1 to 5.1)
Adenoma size, mm 12.8 (5 to 30)
SBP indicates systolic blood pressure; DBP, diastolic blood pressure;
PRA, plasma renin activity; PAC, plasma aldosterone concentration; ARR,
aldosterone:renin ratio.
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were resolved by 10% SDS-PAGE, and poly(ADP-ribose) polymer-
ase (PARP), was visualized by Western blotting.17
Caspase-3 Assay
Cells were transfected and apoptosis was induced as described for
the PARP assay. Caspase-3 activity was quantified in cell extracts
(50 g), using a colorimetric assay kit (CaspACE assay system,
Promega) as described previously.17
TUNEL
Transfected cells were grown in Laboratory-Tek Chamber Slides
(Sigma-Aldrich), and apoptosis was induced with STS (500 nmol/L)
with or without LY294002 (20 mol/L). The TUNEL reaction was
performed according to the manufacturer’s protocol (DeadEnd flu-
orometric TUNEL system, Promega). Slides were mounted in
Vectashield with 4,6-diamidino-2-phenylindole (Vector Laborato-
ries, Burlingame, Calif) and viewed by fluorescence microscopy
(Zeiss, Axio Observer, Göttingen, Germany).
Western Blotting
A chemiluminescent substrate was used to visualize specific bands
binding horseradish peroxidase–linked secondary antibodies (Pierce
Biotechnology).
Statistical Analyses
SAS software, version 8 (SAS Institute Inc., Cary, NC), was used for
statistical analyses. Data are expressed as meanSD, and differences
between variables were evaluated using a parametric test for repeated
measures and a Bonferroni post hoc test. A probability of less than
0.05 was considered statistically significant.
Results
Microarray Analysis of APA Transcript Profiles
and Upregulation of TDGF-1 in APA
Oligonucleotide microarrays were used to perform a tran-
scriptional screening of 8 APA, compared with 3 NA. On the
basis of the filtering algorithm, described in the Methods, 64
probe sets (corresponding to 53 genes) were found to be
differentially expressed in APA compared with NA (33
upregulated, 20 downregulated), and TDGF1 ranked as the
top upregulated gene (average 14.7-fold upregulation). Sup-
plemental Tables I and II list the upregulated and downregu-
lated known genes, respectively. The hierarchical clustering
of differentially expressed genes is presented in Figure 1.
Interestingly, the transcriptional fingerprint of a single uni-
lateral adrenal hyperplasia sample corresponded closely to
that of NA but not to that of APA.
The expression level of TDGF1 was further examined by
real-time PCR on a broader set of adrenal samples (19 APA
and 10 NA) comprising 5 APA and 2 NA already used for the
microarray screening. TDGF1 was also upregulated in this
group of APA (Figure 2A) and was observed in 79% of the
APA samples (n15/19, 21.4-fold compared with NA, Table
2). The microarray data were also confirmed for 3 other
selected genes (TPD52, VSNL1, and IGSF4), thus validating
our gene expression platform (Figure 2B through 2D, Table
2). Finally, the expression of TDGF1 was assayed on distinct
pathological adrenal samples, including cortisol-producing
adenomas from patients with Cushing syndrome (n3),
adrenal incidentalomas (n3), an aldosterone-producing car-
cinoma, and a primary adrenal hyperplasia. In all these
samples, TDGF1 expression levels were comparable to those
present in NA (data not shown). Thus, the upregulation of
TDGF1 appeared as a primary feature of APA and not of
other adrenal diseases.
TDGF-1 Is Localized to the Zona Glomerulosa in
NA Glands
Immunohistochemical staining of frozen tissue sections
demonstrated that TDGF-1 was expressed in the cytoplasm
of NA restricted to the zona glomerulosa (Figure 3A); in
contrast to the immunoreactivity observed in APA, which
was localized to nuclei but cytoplasmic in the surrounding
adrenal cortex (Figure 3B). Nuclear and cytoplasmic
immunoreactivity was confirmed in the pancreas control
specimen that was undetectable in the negative control
(data not shown).
Figure 1. Hierarchical cluster analysis of adrenal samples.
Shown is a hierarchical cluster analysis of differentially
expressed known genes (n42) and tissue samples. Transcript
upregulation is represented in red and downregulation in blue.
The 42 transcripts are represented on the lines and labeled on
the right. Tissue samples are represented in the columns and
labeled on top (1 to 12: 1, unilateral hyperplasia; 2 to 4, NA; 5 to
12, APA). The log color scale of gene expression is shown at
the bottom of the figure.
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Human Adrenocortical Cells (NCI H295R) as a
Model Cell Line to Study the Function of TDGF-1
TDGF-1 was undetectable in H295R cells by semiquantita-
tive RT-PCR and in a pooled sample of first-strand cDNA
from NA, whereas a TDGF-1-specific fragment was ampli-
fied from a pooled sample of first-strand cDNA from APA
(Figure 4); the absence or low level expression of TDGF-1
gene transcription indicates the suitability of this cell line to
study TDGF-1 function in vitro.
TDGF-1 Activates the Akt Signaling Pathway in
H295R Cells
TDGF-1 has been reported previously to activate PI3K/Akt
signaling in diverse cell types.11,18,19 H295R cells were
transfected with either pcDNA3.1/TDGF-1 or pcDNA3.1/
control, and Western blot analysis demonstrated a greater
activation of Akt, revealed by increased phosphorylation of
Akt residues Ser473 and Thr308, in cell lysates from TDGF-
1-transfected H295R cells compared with controls (Figure 5).
Furthermore, increased phosphorylation and therefore inacti-
vation of the Akt substrate glycogen synthase kinase-3 on
residue Ser9 was observed in TDGF-1-transfected H295R
cells (Figure 5).
TDGF-1 Mediates an Increase in Aldosterone
Secretion From H295R Cells That Is Specifically
Blocked by PI3K Inhibitors
H295R cells were transfected with pcDNA3.1/TDGF-1 and
basal aldosterone secretion was measured by radioimmuno-
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Figure 2. Validation of gene overexpres-
sion by real-time PCR. TaqMan gene
expression assays were used in real-
time PCR, performed in triplicate, to
determine fold changes in expression
levels in individual adrenal samples for
each gene, using actin B as the endoge-
nous reference gene. The genes studied
were TDGF1 (A), tumor protein D52
(TPD52) (B), visinin-like 1 (VSNL1) (C),
and immunoglobulin superfamily mem-
ber 4 (IGSF4) (D). A through D, Box plots
of fold changes in expression of the indi-
cated gene in APA (n19) compared
with NA (n10). The horizontal line indi-
cates the median, and the box and the
bar represent the 25th to 75th and 5th to
95th percentiles, respectively. *P	0.05,
**P	0.01.
Table 2. Upregulation of Genes in APA
Gene Fold Change Range No. of APAs Overexpressing Gene
TDGF1 21.4 0.1 to 461.4 15/19 (79%)
TPD52 4.8 0.4 to 21.7 14/19 (74%)
VSNL1 4.1 0.1 to 11.5 10/19 (53%)
IGSF4 1.9 0.3 to 3.8 8/19 (42%)
TaqMan gene expression assays were used in real-time PCR to determine
fold changes in expression levels in individual adrenal samples for each gene
relative to the endogenous reference gene, actin B, performed in triplicate. The
overall fold change in expression of each gene in APA (n19) was calculated
using the 2Ct quantification method, compared with NA (n10). The range
refers to the spread of the individual fold changes (relative quantitation values)
calculated for each APA sample subsequently used to calculate the overall fold
change. Genes were defined as upregulated when the expression of that gene
was 2-fold greater than the average expression in normal adrenals. TPD52
indicates tumor protein D52; VSNL1, visinin-like protein 1; IGSF4, immuno-
globulin superfamily member 4.
Figure 3. TDGF-1 expression in NA and APA. A, In frozen NA,
TDGF-1 expression was evident in the cytoplasm (inset) and
restricted to the zona glomerulosa. B, In contrast, in sections of
frozen APA, TDGF-1 expression was observed predominantly in
the nuclei of APA cells (inset).
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assay and compared with that of cells transfected with
pcDNA3.1/control. Aldosterone secretion was significantly
increased (P	0.005) from TDGF-1-transfected cells, dis-
playing a 3.80.4-fold increase in secreted aldosterone after
72 hours (Figure 6A).
The increased aldosterone secretion was not due to an
increase in cell proliferation (1.060.07-fold change in cell
proliferation after 72 hours for cells transfected with TDGF-
1/control plasmid, n4, SD).
We investigated the effect of angiotensin II (Ang II) and
TDGF-1 on aldosterone secretion. Ang II (10 nM) produced
a 13.71.2-fold increase in aldosterone secretion in control-
transfected cells compared with unstimulated cells and a
15.81.6-fold increase in TDGF-1-transfected cells. TDGF-1
mediates a 3.8-fold increase in aldosterone secretion in
unstimulated cells, and therefore, TDGF-1 does not potentiate
the effect of Ang II in H295R.
The possible involvement of PI3K in TDGF-1-mediated
aldosterone secretion was studied using specific inhibitors
(50 nmol/L wortmannin and 20 mol/L LY294002), which
decreased the TDGF-1-mediated increase in aldosterone se-
cretion (Figure 6B) to levels similar to that of untreated
control cells (1.10.1-fold and 1.30.2-fold increases in
aldosterone secretion in the presence of LY294002 and
wortmannin, respectively; both values not significantly dif-
ferent from untreated control).
H295R cells transfected with TDGF-1 exhibited no signif-
icant difference in cell proliferation compared with control
cells after 72 hours (0.990.04-fold change, n4), and no
significant differences in cell proliferation were detected in
cells transfected with either TDGF-1 or the control plasmid
after 72 hours in the presence of either wortmannin (50
nmol/L) or LY294002 (20 mol/L), 1.020.06 and
0.970.02-fold change in cell proliferation in control cells in
the presence of LY294002 and wortmannin, respectively, and
1.010.04 and 0.970.02-fold change in TDGF-1-
transfected cells in the presence of LY294002 and wortman-
nin, respectively (n4).
TDGF-1 Protects H295R Cells From Apoptosis,
and This Effect Is Blocked by a PI3K Inhibitor
TDGF-1 has been reported to function as a survival factor
with an antiapoptotic effect in human cervical carcinoma
cells via a PI3K-dependent signaling pathway.19 Induction of
apoptosis by STS and specific detection of PARP by Western
blotting demonstrated that cleavage of catalytically active
PARP was relatively protected in TDGF-1-transfected cells:
Figure 7A shows an increased ratio of the uncleaved:cleaved
forms of PARP in these cells; thus, the inactive, cleaved form
of PARP, a hallmark of apoptosis, is relatively more abundant
in control cells.
In addition, the increase in caspase-3 activity in response to
STS was markedly reduced in cells transfected with TDGF-1:
a 19.73.7-fold increase in caspase-3 activity in control cells
(caspase-3 activity in STS-stimulated/unstimulated cells)
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Figure 4. Semiquantitative RT-PCR of TDGF-1 in H295R cells
and adrenal samples. Semiquantitative PCR amplification of a
TDGF-1 fragment (490 bp) using templates of either first-strand
cDNA reverse transcribed from total RNA isolated from H295R
cells or pooled cDNAs produced from APA transcripts (n19) or
from NA (n10). GAPDH was used as the endogenous control
gene.
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Figure 6. TDGF-1 mediates a PI3K-dependent increase in aldoste-
rone secretion from H295R cells. H295R cells were transfected
with TDGF-1 or control (Ctrl) plasmids, and secreted aldosterone
was assayed in culture medium by radioimmunoassay. A, Data are
shown as fold increases in aldosterone secretion from TDGF-1-
transfected cells compared with controls and are the means of 4
independent experiments performed in duplicateSD. *P	0.005
for all comparisons. B, Cells were transfected with Ctrl (black col-
umns) or TDGF-1 (white columns) plasmids and incubated with or
without wortmannin (50 nmol/L) or LY294002 (20 mol/L). Data are
shown as fold increases in aldosterone secretion compared with
controls and are the means of 4 independent experiments per-
formed in duplicateSD *P0.002, **nonsignificant difference
compared with untreated control (left column).
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compared with a 3.60.6-fold increase in caspase-3 activity
in TDGF-1-transfected cells (Figure 7B).
The possible involvement of PI3K in TDGF-1-mediated
decreased sensitivity to apoptotic stimuli in H295R cells was
studied using the TUNEL assay. In agreement with an
antiapoptotic effect of TDGF-1, the strong fluorescent label-
ing observed in the nuclei of control cells was greatly
decreased in TDGF-1-transfected cells. Furthermore, in the
presence of the PI3K inhibitor LY294002 (20 mol/L), this
protective effect of TDGF-1 toward apoptotic stimuli was
partially blocked (Figure 8).
Discussion
PA is the most common form of endocrine hypertension, and
APA comprises a frequent subtype of this disease (30% to
40% of the total). The removal of the adenoma in patients
with APA normalizes the excessive aldosterone secretion,
characteristic of this condition, and, as a consequence, cures
or markedly improves the hypertensive status.
This work defines TDGF-1 as a highly upregulated gene in
APA compared with NA tissue. In agreement with previous
transcriptional screens, we observed an increased expression
of both aldosterone synthase (CYP11B2) and the 5-hydroxy-
tryptamine receptor 4 (HTR4)6,7,9; however, we did not find
evidence for elevated expression of either the luteinizing
hormone receptor8 or the Ca2/calmodulin-dependent protein
kinases.9 This could be due to heterogeneity of the APA
phenotype or to differences in normal subjects and patient
selection: for example, in this study, APA were used from
patients with florid forms of PA, adrenalectomized after
performing adrenal venous sampling using particularly strict
criteria both for successful cannulation and lateralization.
This study assigns a functional role for TDGF-1 in aldo-
sterone secretion and in the protection from apoptosis in
human adrenocortical carcinoma cells (NCI H295R). We
show that inactivating PI3K with specific inhibitors blocks
the increase in aldosterone secretion mediated by TDGF-1 in
H295R cells and at least partially blocks the reduction in
sensitivity to apoptosis. PI3K activation is followed by Akt
phosphorylation, a key effecter of PI3K-mediated cell
survival.20,21 The present study demonstrates that the cell
survival effect and the increase in aldosterone secretion are
associated with the activation of Akt by increased phosphor-
ylation in the C-terminal regulatory domain on residue
Ser473 and in the catalytic domain on residue Thr308.
Consistently, an increase in Akt signaling was demonstrated
further by the enhanced Ser9 phosphorylation of the Akt
substrate glycogen synthase kinase-3.
The antiapoptotic effect of TDGF-1 associated with Akt
activation is consistent with the known effect of Akt in
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Figure 7. TDGF-1 confers reduced sensitivity to apoptosis in
H295R cells. A, The hydrolysis of full-length PARP (116 kDa) to
the inactive form (89 kDa) analyzed by Western blotting of
lysates of TDGF-1 or control (Ctrl) plasmid-transfected cells
after incubation with or without STS (500 nmol/L). A representa-
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Caspase-3 was assayed in cell lysates of TDGF-1 or Ctrl-
transfected cells after incubation with or without STS (500
nmol/L) for 16 hours. Data are shown as fold changes in
caspase-3 activity in the presence of STS compared with cells
incubated in the absence of STS and are the means of 3 inde-
pendent experiments performed in duplicateSD. *P0.01.
   
   
+S
TS
+L
Y
29
40
02
   
   
   
   
S
TS
   
   
   
   
  U
nt
re
at
ed
CTRL                                                  TDGF1
Dapi                        TUNEL                           Dapi                       TUNEL Figure 8. The antiapoptotic effect of
TDGF-1 in H295R cells is blocked by
PI3K inhibition. DNA fragmentation as a
marker for apoptosis was detected by
terminal deoxynucleotidyl transferase
biotin-dUTP nick end labeling (TUNEL)
and fluorescent microscopy in cells trans-
fected with TDGF-1 or control plasmid
and incubated with STS (500 nmol/L) for
2 hours with or without LY294002
(20 mol/L). Cells were mounted in
Vectashield containing 4-6-diamidino-2-
phenylindole (Dapi), and images were
taken by fluorescent microscopy (taken at
a 40 magnification) using appropriate
filters. Representative fields are shown
from experiments performed 3 times.
6 Hypertension June 2010
 at Biblioteche biomediche Universita' di Torino on April 27, 2010 hyper.ahajournals.orgDownloaded from 
promoting cell survival via the phosphorylation and inactiva-
tion of the proapoptotic protein Bad.22 In agreement with the
present study, other groups have demonstrated that TDGF-1
activates PI3K/Akt signaling, for example, in mouse mam-
mary epithelial cells18 and in cervical carcinoma cells, leading
to the phosphorylation and inactivation of glycogen synthase
kinase-319; this latter study also demonstrated an antiapo-
ptotic effect of TDGF-1 that was decreased by a specific
PI3K inhibitor. Furthermore, the suppressed tumor growth in
vivo, resulting from antibody blockade of TDGF-1,12,23 was
related to increased apoptosis mediated by c-Jun-N-terminal
kinase and inhibition of Akt phosphorylation.23
Other factors have been identified that increase aldosterone
secretion from adrenocortical cell lines or from cells isolated
from the zona glomerulosa: for example, sphingosine-1-
phosphate stimulates aldosterone secretion via the PI3K/Akt
and mitogen-activated protein/extracellular signal–regulated
kinase pathways24; an adipokine, CTRP1, expressed specifi-
cally in the zona glomerulosa of the adrenal cortex, increased
aldosterone production in H295R cells.25 Furthermore, the
phosphoprotein Disabled-2, expressed in the zona glomeru-
losa and zona intermedia of the rat adrenal gland, increased
aldosterone secretion, although under conditions of Ang II
stimulation.26 However, to our knowledge, this is the first
study that in addition to identifying a gene transcript specif-
ically overexpressed in APA, also demonstrates potentially
relevant functional roles in the adrenal cell model, NCI
H295R, and provides evidence for the underlying mechanism
via PI3K/Akt signaling.
TDGF-1 functions as an essential cofactor for signaling by
the transforming growth factor- family ligand Nodal during
early embryogenesis and belongs to the epidermal growth
factor–CFC family of proteins that are present in diverse
species such as zebrafish, Xenopus, and mouse, as well as
humans.27 TDGF-1 is overexpressed in many human cancers,
such as breast, pancreatic, ovarian, and colon cancers. Fur-
thermore, a functional role for TDGF-1 in tumor growth is
suggested because its expression can transform some mam-
mary cell lines; in addition, antibody blockade of TDGF-1
suppresses tumor growth in vivo,12,23 and antisense inhibition
of TDGF-1 results in the loss of the transformed phenotype of
colon carcinoma cells.28 In normal adult tissues, TDGF-1 is
primarily expressed in mammary glands during pregnancy
and lactation; this is the first report of TDGF-1 expression in
the NA gland and in APA. TDGF-1 is primarily distributed as
a plasma membrane–bound protein but can also exist in a
soluble form, with a dual function as both receptor and
growth factor: however, we show here that, in NA cells,
TDGF-1 has a cytoplasmic location, in contrast to the patholog-
ical state in APA, where TDGF-1 is localized exclusively to the
nucleus. Nonetheless, a cytoplasmic subcellular distribution for
TDGF-1 has indeed been reported previously.29,30 The reason
for the nuclear versus cytoplasmic localization of TDGF-1 in
APA or normal tissue, respectively, is unclear. It could be
proposed that TDGF-1, in addition to its well-characterized
role as a coreceptor for Nodal in early embryogenesis, may
undergo nuclear translocation under certain conditions in
adult tissues and subsequently regulate gene expression,
thereby mediating other cellular processes. Such a precedent
has been described previously. For example, epidermal
growth factor receptor family members, in addition to the
traditional epidermal growth factor receptor pathway involv-
ing transduction of mitogenic signals via the activation of
signaling cascades, can also translocate to the nucleus and
regulate gene expression; a number of other receptor tyrosine
kinases and cytokine receptors also undergo similar nuclear
localization,31 but further studies would be required to estab-
lish whether this is the case for TDGF-1.
Future studies should address whether the upregulation of
TDGF-1 is specific to a particular subtype of APA (eg, Ang
II responsive/unresponsive). The number of Ang II–respon-
sive patients in the present study was too small to adequately
answer this question.
This work defines TDGF-1 as a highly upregulated gene in
APA compared with NA cortex and assigns a functional role
for TDGF-1 in aldosterone secretion and in the protection
from apoptosis in human adrenocortical carcinoma cells via
PI3K/Akt signaling. Changes in the level of TDGF-1 expres-
sion in specific cell populations of the adrenal gland, that is,
in the zona glomerulosa, may constitute one of several
changes that are important in the pathogenesis of an APA, in
which the cumulative effect of a number of genetic alterations
is required for the initiation of APA formation and subse-
quent autonomous hypersecretion of aldosterone.
Perspectives
The present study provides evidence for a potential role of
TDGF-1 in the pathogenesis of APA and highlights a dual
function for this epidermal growth factor–like protein in the
inhibition of apoptosis and in increasing aldosterone secretion
from adrenal cells via deregulated Akt signaling. In addition,
we demonstrate significant upregulation or downregulation of
a number of other genes compared with NA, thus providing
the basis for future studies that address the role of genomic
alterations in the pathophysiology of APA.
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Expanded Materials and Methods  
 
Patient selection  
Patients were studied following the procedure described in detail elsewhere (1).  Briefly, 
patients were screened using the aldosterone (PAC)/plasma renin activity (PRA) ratio (ARR) 
and PA was confirmed using the intravenous saline load test. (2). All patients with confirmed 
PA underwent CT scanning and adrenal vein sampling (AVS). AVS was considered successful 
if the adrenal vein/inferior vena cava cortisol gradient was at least 3; lateralization was 
considered when the aldosterone/cortisol ratio (A/C) from one adrenal was at least 4 times that 
of the other adrenal gland (lateralization ratio, LR) with an A/C in the contralateral lower than 
the A/C in the peripheral vein. Finally, all patients with PA were screened for GRA using a 
long-PCR technique (3). A definitive diagnosis of APA was made as defined elsewhere (1). All 
patients with APA were adrenalectomized by laparoscopy. NA were obtained from 
normotensive individuals undergoing laparoscopic nephrectomy for localized renal carcinomas: 
in all cases, careful histological examination excluded the involvement of the adrenal in the 
tumor lesion. The study was approved by our institutional ethics committee and informed 
consent was obtained from all subjects.  
 
Microarray  
RNA samples used for microarray experiments (n=12) were assayed for purity and 
quality using an Agilent Bioanalyzer according to the manufacturer’s instructions. The gene 
expression profiling platform was oligonucleotide array Affymetrix GeneChip HG-U133 Plus 
2.0, that allows the study of more than 47 000 transcripts. cRNA synthesis, labeling, 
hybridization and chip scanning were performed following the manufacturer’s protocols. CEL 
files were analyzed using dChip 2008 Software (4). Briefly, the data underwent invariant set and 
running median smoothing normalization in order to adjust for differences in overall array 
brightness. The expression levels of probe sets were then computed using the model-based 
expression indexes (MBEI). We retained for further analysis: (i) probe sets receiving a presence 
(P) call across all samples and (ii) probe sets receiving a P call only in case (APA, n=8) or only 
in control (normal adrenals, n=3) samples. Finally, filtered probe sets were ranked based on the 
ratio between their average expression level in case and control samples. Only transcripts with a 
lower 90% bound of fold change >2.0 or <-2.0 and an absolute signal intensity difference 
between case and control sets >100 were considered as differentially expressed. Hierarchical 
cluster analysis of genes and samples was performed applying correlative algorithms, after 
averaging of redundant probe sets. 
 
RNA extraction from adrenal tissues 
Adrenal tissue (approx. 100 mg) was homogenized (Ultra-Turrax T8 IKA tissue 
homogenizer, Staufen, Germany) in  1 mL TRI-reagent (Sigma-Aldrich Corp., St. Louis, MO) 
and processed according to the manufacturer’s instructions. RNA purity and quality was 
analyzed by spectrophotometry (A260/280 nm) and agarose gel electrophoresis. For RNA 
positive controls the outer part of the cortex of fresh adrenal gland was dissected and processed 
similarly. The histology of parallel specimens were checked on frozen sections, confirming that 
the tissue used for the RNA analysis spanned across the zona glomerulosa and part of the 
fasciculata zone of the adrenal cortex. The ideal control tissue for expression studies with APA 
is unknown since adenoma cells display a histological phenotype of both zona glomerulosa and 
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zona fasciculata cells and often appear as hybrid cells; furthermore, it has been demonstrated 
that APA cells express genes that, in normal adrenal tissues, are exclusively expressed in either 
the zona glomerulosa, such as, CYP11B2, or in the zona fasciculata, such as, CYP17 (5, 6). 
 
Gene expression assays 
Quantitative real time-PCR (qRT-PCR) was performed in 2-steps. Reverse transcription was 
performed using 5 µg total RNA, 250 ng random primers (Invitrogen Corporation, Carlsbad, 
CA), 500 µmol/L dNTPs, 10 mmol/L DTT and SuperScript II reverse transcriptase (200 units, 
Invitrogen) in First-Strand Buffer in a 20 µL reaction volume, as described by the manufacturer. 
Quantitative PCR was subsequently performed in triplicate using TaqMan gene expression 
assays (Applied Biosystems, Foster City, CA) on an Applied Biosystems ABI 7500 instrument 
following standard protocols. Gene expression levels were analyzed using the 2-∆∆Ct relative 
quantification method, using β-actin as the endogenous reference gene. Pre-designed Primer-
TaqMan probe assays were purchased from Applied Biosystems. 
 
Semi-quantitative RT-PCR 
 Total RNA was extracted from 100 mm diam. plates of sub-confluent cells (RNeasy mini 
kit, Qiagen, Stanford Valencia, CA). First strand cDNA were generated from 5 µg total RNA 
using Superscript II reverse transcriptase (Invitrogen), according to the manufacturer’s 
instructions and the cDNA was used as template for PCR amplification of a TDGF-1 fragment 
(forward primer, 5’cgatgctaacgcctcttttc3’; reverse primer, 5’catcacagccgggtagaaat3’): 95°C, 5 
min; 35 cycles (95°C, 20 sec; 55°C, 20 sec; 72°C, 1 min); 72°C, 10 min. Pooled samples of 
APA cDNA (n=19, equal volume of each cDNA) or NA cDNA (n=10), reverse transcribed from 
total RNA, were used similarly as templates for PCR amplification of TDGF-1, and GAPDH 
was used as the endogenous reference gene and amplified similarly but using 25 PCR cycles 
(forward primer, 5’gagtcaacggatttggtcgt3’; reverse primer, 5’tgtggtcatgagtccttcca3’). 
 
PCR cloning of TDGF-1 
 The full-length coding region of the TDGF-1 cDNA was PCR amplified from first strand 
cDNA using pfu polymerase (Promega , Madison, WI) from a subject expressing the highest 
level of the TDGF-1 transcript, as determined by qRT-PCR. The primers 5’gcctcttttcccctaattg3’ 
(forward)  and 5’agcagcagcctttactggtc3’ (reverse) were used to amplify a TDGF-1 669 bp 
cDNA fragment that was subcloned into pcDNA3.1 and the PCR-amplified region was 
subsequently sequenced to verify the absence of mutations. 
 
Immunohistochemistry 
 Frozen sections of APA or adjacent normal cortical adrenals were cut (4 µm), quenched 
for 5 min with DAKO Peroxidase Block (Dako, Carpinteria, CA, USA) and incubated for 1 h at 
RT with anti-human TDGF-1 polyclonal antibody (ab19917, Abcam plc, Cambridge, UK, 200 
µL, 1:20 dilution). Sections were washed and incubated for 30 min with Envision system-HRP 
labeled polymer (Dako) conjugated with anti-rabbit secondary antibody. Staining was 
completed by a 5 min incubation with 3,3’-diaminobenzidine (DAB) substrate-chromogen and 
nuclei were counterstained with hemalum for 5 min. Sections from pancreatic tissue known to 
express TDGF-1 were used as a positive control (7). The primary antibody was omitted as a 
negative control. 
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Cell culture 
 NCI H295R human adrenocortical carcinoma cells (8) were cultured in RPMI 1640 
medium without phenol red (Gibco, Billings, MT) supplemented with 2% FBS, insulin-
transferrin-selenium A, L-glutamine (292 µg/mL), streptomycin (100 µg/mL) and penicillin 
(100 U/mL) (all from Gibco) and maintained at 37°C in a humidified 5% CO2 incubator.  
 
Transfection of H295R cells 
 Sub-confluent cells were split 1:2, 24 h before electroporation with the Amaxa 
nucleofector (Amaxa Biosystems, Cologne, Germany). Cells were harvested and resuspended 
(2x106 cells) in Nucleofector solution R (100 µL), and electroporated with 2 µg of plasmid 
(programme P20). Resuspended cells were cultured in 6-well plates and medium was changed 
after 24 h (1.5 mL). Cell viability assays (Trypan blue exclusion), performed before and after 
electroporation, indicated 38-50% cell viability. Transfection efficiency was routinely checked 
by electroporation of the pmaxGFP plasmid and fluorescence microscopy that demonstrated at 
least 60% transfection efficiency up to 96 h post-transfection (data not shown). 
 
Aldosterone measurements 
 H295R cells were transfected by Amaxa electroporation with pcDNA3.1/TDGF-1 or 
control plasmid, pcDNA3.1/Ctrl (TDGF-1 cDNA inserted in the antisense direction with respect 
to the pCMV promoter). Some cells were incubated with PI3K inhibitors wortmannin (50 
nmol/L) or LY294002 (20 µmol/L). Culture medium was assayed for aldosterone in duplicate 
by radioimmunoassay as described previously (1). Aldosterone measurements were normalized 
by protein concentrations of cell lysates (9). 
 
Cell proliferation assay 
 H295R cells were transfected, viable cells (0.2% Trypan blue exclusion) were counted 
and the viable cell density was adjusted to 104 cells/100µL medium. Cells were seeded in 96-
well plates (104 cells/well) and after 24 h medium was replaced (100 µL) and cells incubated a 
further 72 h. Cell Titer solution (20 µL) was added (Cell Titer 96 aqueous one solution cell 
proliferation assay kit, Promega, Madison, WI), and cell proliferation quantified following the 
manufacturer’s protocol. 
 
Apoptosis assays 
 PARP assay- H295R cells were transfected, after 24 h they were incubated for 16 h ± 
staurosporine (500 nmol/L, Sigma-Aldrich) to induce apoptosis. Cells were washed with PBS, 
lysed and sonicated directly in SDS-PAGE sample buffer (300 µL). Samples (15 µL) were 
resolved by 10% SDS-PAGE and the inactivation of the 116 kDa DNA repairing enzyme Poly 
(ADP-ribose) polymerase (PARP) to the 89 KDa fragment, was visualised by Western blotting 
using an anti-PARP monoclonal antibody, as described previously (10). 
 
 Caspase-3 assay- Cells were transfected and apoptosis was induced as described for the 
PARP-assay. Caspase-3 activity was quantified in cell extracts (50 µg), using a colorimetric 
assay kit (CaspACE assay system, Promega) that employed the substrate N-acetyl-DEVD-p-
nitroanilide as described previously (10).  
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 TUNEL- H295R cells were transfected as described above. Cells were added to single-
well Lab-Tek Chamber Slides (Sigma-Aldrich) containing 4 mL medium. After 24 h, medium 
was changed (1.5 mL) and cells grown a further 24 h. Apoptosis was induced for 2 h with 
staurosporine (500 nmol/L) and incubated ± the PI3K inhibitor LY294002 (20 µmol/L, cells 
pre-incubated 30 min), and the TUNEL reaction was performed according to the manufacturer’s 
protocol (The DeadEnd fluorimetric TUNEL system, Promega). Slides were mounted in 
Vectashield with Dapi (Vector Laboratories, Burlingame, CA) and viewed by fluorescence 
microscopy.  
 
Western Blotting 
 The primary antibodies used were mouse monoclonal anti-PARP (F-2, 1:500 dilution, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA), rabbit polyclonal anti-actin (1:5000 dilution, 
Sigma-Aldrich) and rabbit monoclonal antibodies to phospho Ser473 Akt (D9E), phospho 
Thr308 Akt (C31E5) and pan Akt (C67E7), as well as phospho-Ser9-GSK-3β (5B3) and pan 
GSK-3β (27C10) (all used at 1:1000 dilution, Cell Signaling Technology Inc., Beverly, MA). 
Nitrocellulose membranes were stripped of primary and secondary antibodies by incubating in 
Restore Western Blot Stripping buffer (Pierce Biotechnology, Rockford, IL) for 15 min at 37°C, 
washed, blocked and incubated with the subsequent primary antibody. A chemiluminescent 
substrate (ECL) was used to visualize specific bands binding HRP-linked secondary antibodies 
(Pierce Biotechnology). 
 
Statistical analyses 
SAS V8 software (SAS Institute Inc., Cary, NC) was used for statistical analyses. Data are 
expressed as mean ± s.d. and differences between variables were evaluated using a parametric 
test for repeated measures and a Bonferroni post-hoc test. A probability of less than 0.05 was 
considered statistically significant. 
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lower 
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TDGF1               teratocarcinoma-derived growth factor 1 (Cripto)         NM_003212 1 14.7 3.66 43 
CYP11B2                                           aldosterone synthase X54741 1 8.51 4.57 25.27 
LRRC2                             leucine rich repeat containing 2 NM_024512 1 7.69 2.8 25.7 
ALDH1A2 aldehyde dehydrogenase. family 1, member A2                                                                       AB015228 1 7.13 3.5 14.84 
SLC24A3                                             Na/K/Ca exchanger NM_020689 2 6.81 4.1 11.08 
SNAP25                          synaptosomal-associated protein NM_003081 1 6.41 2.72 13.48 
HOP                                        homeodomain-only protein AB059408 2 6.28 2.88 20.56 
CLRN1                                                                    clarin 1 AF482697 1 5.1 2.38 17.46 
LMOD1 leiomodin 1 BC001755 1 5.05 2.92 12.65 
TPD52                                                   tumor protein D52 AA524023 3 4.34 2.98 6.79 
HTR4                               5-hydroxytryptamine receptor 4 AJ131724 1 4.33 2.05 7.79 
HLA-DQA1                Major histocompatability complex, IIDQ alpha1 BG397856 1 3.91 2.12 9.83 
ATP2A3                                      ATPase, Ca2+ transporter NM_005173 1 3.86 2.05 7.08 
CALN1                                                             calneuron 1 AF282250 2 3.82 2.29 7.15 
VSNL1                                                           visinin-like 1 NM_003385 1 3.63 2.14 7.77 
IGSF4                 immunoglobulin superfamily, member 4 NM_014333 3 3.62 2.56 5.89 
ENPP2                                                                  autotaxin D45421 1 3.37 2.08 4.86 
PRRX1                                     paired related homeobox 1 NM_006902 1 3.31 2.4 4.71 
PCDHGC3                                       protocadherin gamma AF152504 1 3.24 2.2 4.51 
ABAT                          4-aminobutyrate aminotransferase AF237813 2 3.14 2.35 4.13 
LRRC39                          leucine rich repeat containing 39 BF111992 1 3.01 2.01 4.72 
DUSP4                                dual specificity phosphatase 4 NM_001394 1 2.84 2.03 3.84 
SV2A                              synaptic vesicle glycoprotein 2A NM_014849 1 2.82 2.09 4.13 
DKFZP586H2123                                                                 regeneration associated muscle protease     AI671186 1 2.8 2.03 3.9 
TIMP3                    tissue inhibitor of metalloproteinase 3 BF347089 1 2.61 2.3 3 
 
 
 
Table S1. Microarray: genes with elevated expression levels in APAs compared to normal adrenals 
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PCK1                    phosphoenolpyruvate carboxykinase 1 NM_002591 1 -29.77 -7.4 -252.33 
GLYAT                                  glycine-N-acyltransferase AW024233 1 -17.96 -6.39 -1E+08 
PPP1R1A         protein phosphatase 1, regulatory (inhibitor) subunit 1A NM_006741 1 -15.89 -4.86 -97.96 
ADIPOQ                                           Adiponectin, C1Q NM_004797 1 -14.79 -4.83 -165.98 
FABP4                                fatty acid binding protein 4 NM_001442 2 -14.01 -3.57 -41.6 
PLIN                                                                 perilipin NM_002666 1 -13.41 -3.11 -39.69 
CD36                                                      CD36 antigen (collagen type I receptor) NM_000072 3 -7.83 -4.98 -14.35 
TSSK1B                  testis-specific serine kinase 1 AF348076 1 -7.74 -2.63 -50.6 
ATP1B3                     ATPase. Na+/K+ transporting, beta 3 polypeptide AI928218 1 -4.96 -3.62 -7.38 
FABP5                               fatty acid binding protein 5 NM_001444 1 -4.39 -2.22 -7.29 
ALS2                               amyotrophic lateral sclerosis 2 AB046783 1 -4.16 -2.72 -7.51 
SFRP2                      secreted frizzled-related protein 2 AF311912 1 -3.94 -2.14 -6.69 
GNB1L                     G protein, beta polypeptide 1-like NM_024627 1 -3.64 -2.24 -6.88 
PAPSS2       3'-phosphoadenosine 5'-phosphosulfate synthase 2 AI821404 1 -3.39 -2.47 -4.7 
NUB1    negative regulator of ubiquitin-like proteins 1 AK026433 1 -2.91 -2.19 -3.93 
IL1RL1                              Interleukin 1 receptor-like 1 NM_003856 1 -2.62 -2.06 -3.3 
SULT1E1     sulfotransferase family 1E, estrogen-preferring, member 1 U55764 1 -2.45 -2.03 -3.01 
 
 
Table S2.  Microarray: genes with decreased expression in APAs compared to normal adrenals 
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